In the retina, peptidergic signalling participates in multiple circuits of visual information processing.
Retina and neuropeptides
The defined input of the mammalian retina, its discrete output, accessibility, laminar organisation, and small number of principal cell types have promoted an understanding of retinal circuitry and structure-functional relationship. Beside its use for investigations on visual information processing, the mammalian retina has been extensively used as an experimental model of the central nervous system. Indeed, it is part of the central nervous system and it is separated at the same time, allowing easy experimental approaches. In addition, the mammalian retina displays the complexity typical of the brain while having an ordered, layered structure that is conserved throughout its extension (Fig   1) . The retina is composed of five principal neuronal cell types, including photoreceptors (the light sensitive cells in the retina), bipolar, horizontal, amacrine, and ganglion cells. A sixth type is that of The most heterogeneous retinal cell type is that of amacrine cells, which can be divided into numerous populations on the basis of their neurochemical phenotypes. In this regard, a wide variety of neuroactive substances are expressed in the mammalian retina. Over the last three decades, several neuropeptides have been investigated and some knowledge is now available of their potential physiological relevance (Bagnoli et al., 2003) . In particular, neuropeptides are principally expressed by populations of sparsely distributed, mostly GABAergic amacrine cells and by some ganglion cells. In contrast, neuropeptide receptors are expressed by variegated retinal cell populations, suggesting that peptidergic signalling participates in multiple circuits of visual information processing. Among neuropeptides, somatostatin, or somatotropin release inhibiting factor (SRIF), has been widely investigated in the retina. SRIF is produced from a single gene in two bioactive products: SRIF-14 and SRIF-28 (Olias et al., 2004) . SRIF produces its effects by activating five heptahelical transmembrane G-protein coupled receptors, which have been cloned and named sst 1 to sst 5 in accordance with IUPHAR recommendations (Hoyer et al., 1995) . Here, we provide a review of the latest advances on the role of SRIF and its receptors in the mammalian retina.
The somatostatinergic system in the retina
The expression and the localisation of SRIF and of its receptors (both at mRNA and at protein level) in mammalian retinas has been reviewed in recent years (Casini et al., 2005; Thermos, 2003) .
There is a general agreement that such a distribution reflects the pleiotropic functions of retinal SRIF as a result of the multiple signalling actions of its receptors.
Expression of somatostatin
In general, SRIF immunoreactivity is localised to sparsely distributed, wide-field amacrine and/or displaced amacrine cells and, in some instances, in a subset of ganglion cells. In particular, in the mouse (Cristiani et al., 2002) , rat (Larsen et al., 1990; Sagar et al., 1985) , guinea pig (Spira et al., 1984; Tornqvist et al., 1982) and human retina (Tornqvist and Ehinger, 1988) , SRIF-containing cells are detected in both the inner nuclear layer and the ganglion cell layer. In the mouse retina, the population of SRIF-containing amacrine cells is sparsely distributed to all retinal regions, while the population of displaced amacrine cells is confined to the ventral retina (Cristiani et al., 2002) . In the rabbit, cat and primate retina, most SRIF immunoreactive cells are displaced amacrine cells that are predominantly distributed to the ventral retina (Engelmann and Peichl, 1996; Rickman et al., 1996; White et al., 1990; Marshak, 1989; Mitrofanis et al., 1989; Sagar and Marshall, 1988; Sagar, 1987) .
In spite of the very sparse distribution of SRIF somata, SRIF processes extensively arborise in the inner plexiform layer of all retinal regions. A few ganglion cells displaying SRIF immunoreactivity have been reported in the retina of the new world monkey Tupaia belangeri (Engelmann and Peichl, 1996) and of the cat, where these SRIF-immunoreactive ganglion cells have been identified as a small subset of OFF-center alpha ganglion cells, mostly localised to the inferior retina (White and Chalupa, 1991) . Finally, a transient population of SRIF-containing ganglion cells has been discovered in the rat retina during postnatal development (Xiang et al., 2001; Fontanesi et al., 1997) .
Expression of somatostatin receptors
Immunohistochemical data show that SRIF receptors are expressed by a variety of retinal cell populations. In rat, rabbit and mouse retinas, sst 1 is predominantly expressed by SRIF-containing amacrine cells (Dal Monte et al., 2003b; Cristiani et al., 2000; Helboe and Moller, 1999) . In the rabbit retina, it is also found on all the dopaminergic amacrine cells (Cristiani et al., 2000) . Of the two sst 2 isoforms, sst 2A has been localised in rat, rabbit and mouse retinas, where it displays slightly different patterns (Cristiani et al., 2002; Petrucci et al., 2001; Vasilaki et al., 2001; Fontanesi et al., 2000; Helboe and Moller, 1999; Johnson et al., 1999; Johnson et al., 1998) . In the rat retina, sst 2A has been localised to amacrine cells, including tyrosine hydroxylase-containing amacrine cells, to rod and cone bipolar cells and to horizontal cells (Johnson et al., 1999) . In rabbits, these receptors are expressed mainly by rod bipolar and by sparsely distributed amacrine cells that have been reported to lack (Johnson et al., 1998) or to partially express tyrosine hydroxylase immunoreactivity. In the mouse retina, sst 2A immunoreactivity has been reported in rod bipolar cells, horizontal cells, and in amacrine cells (Fig 2) , including glycinergic amacrine cells and the population of tyrosine hydroxylase-containing, dopaminergic amacrine cells (Cristiani et al., 2002) . The sst 2B isoform in the rat retina is predominantly found on the membrane of photoreceptors, indicating SRIF actions in the outer retina (Vasilaki et al., 2001 ). In the human retina, both sst 1 and sst 2A have been immunohistochemically localised throughout all retinal layers (Klisovic et al., 2001; van Hagen et al., 2000) and in endothelial cells of retinal blood vessels (Klisovic et al., 2001) . Regarding sst 4 , it has been identified with immunohistochemistry in sparse ganglion cells of the mouse retina (Cristiani et al., 2002) . Finally, sst 5 has been recently reported in cholinergic, dopaminergic and SRIF-containing amacrine cells and in putative ganglion cells of the rat retina (Ke and Zhong, 2007) . These data appear to be in contrast with a previous work reporting lack of sst 5 immnuoreactivity in the rat retina (Vasilaki et al., 2002) . Data concerning the retinal localization of sst 3 are not available, however its mRNA has been detected in rat (Mori et al., 1997) , mouse (Cristiani et al., 2002) , and human (Klisovic et al., 2001; van Hagen et al., 2000) retinas.
Profound alterations of the levels of SRIF expression as well as of that of specific ssts have been detected in retinas of mice in which sst 1 or sst 2 genes are genetically deleted (Casini et al., 2004; Dal Monte et al., 2003b) . In particular, although changes in the expression of SRIF mRNA have not been reported in these knock-out (KO) retinas, sst 1 deletion causes an increased content of SRIF peptide, whereas SRIF content decreases after sst 2 loss. In addition, sst 1 and sst 2 have been found to compensate for each other. Indeed, as a consequence of sst 1 deletion, sst 2 becomes overexpressed, whereas in sst 2 KO retinas, sst 1 expression is drastically increased. The fact that SRIF binding sites in sst 1 KO retinas have a density similar to that of wild-type (WT) retinas suggests that the relative proportion of SRIF receptors does not change as a consequence of sst 1 deletion and indicates that the loss of sst 1 can be totally compensated by an increase in sst 2 . Compensatory mechanisms at the level of SRIF receptor density also occur in the absence of SRIF since an upregulation of SRIF binding sites has been recently reported in SRIF KO mouse retinas (Mastrodimou et al., 2006b ). In addition, in these retinas, all SRIF receptor mRNAs, with the only exception of sst 4 mRNA, are expressed at significantly higher levels than in WT retinas (Casini et al., 2005) .
Signalling mechanisms
It is generally accepted that the pleiotropic cellular functions of SRIF are a result on the one hand of the widespread distribution of the SRIF system, and on the other of the variety of signalling mechanisms activated by SRIF receptors . In particular, as summarised in Cervia et al., 2005b) . These data have been collected mainly over the last decade using in vitro systems of recombinant and/or native models. In addition, different SRIF analogues may induce distinct conformations of the receptor/ligand complex, preferentially coupled to receptor signalling (Tulipano and Schulz, 2007) .
For these reasons, our current understanding of receptor subtype-selective signalling reflects a rather complicated picture and parallels between these data and the real in vivo conditions are not so obvious.
Signalling mechanisms in the retina
At present, little is known about SRIF signalling in the mammalian retina. For instance, SRIF inhibits adenylyl cyclase activity in the sheep retina (Colas et al., 1992) . In contrast, it increases adenylyl cyclase activation in amacrine cells of the rat retina (Feigenspan and Bormann, 1994) .
Where the specific receptor subtype involved has been studied, it has been found that sst 2 inhibits adenylyl cyclase activity in the mouse retina, probably through G o -proteins (Pavan et al., 2004) .
sst 2 coupling to G o -proteins has been also demonstrated in the rabbit retina (Vasilaki et al., 2003) .
Interestingly, in the mouse retina, sst 1 inhibits adenylyl cyclase activity only after elimination of the sst 2 response, suggesting that there may be interactions between sst 1 and sst 2 when they signal via adenylyl cyclase (Pavan et al., 2004) . In addition, although NADPH diaphorase staining does not colocalise with sst 1 , sst 2 or sst 4 in the mouse retina (Mastrodimou et al., 2006b) , the colocalisation of sst 2 with NADPH diaphorase in rod bipolar cells and photoreceptor cells of both rat and rabbit retinas has been reported (Vasilaki et al., 2001) , suggesting a role of SRIF in the regulation of nitric oxide. Consistently, sst 2 activates nitric oxide synthase in human retinal pigment epithelial cells (Vasilaki et al., 2004) and in the rat retina (Vasilaki et al., 2002) . Once generated, nitric oxide does not exert its effect via specific receptors but it diffuses across synaptic membranes to activate soluble guanylate cyclase, thus increasing intracellular levels of cGMP. Accordingly, in the rat retina, sst 2 has been recently shown to mediate SRIF-induced increase of cGMP levels (Mastrodimou et al., 2006a (Petrucci et al., 2001) . sst 2 negative coupling to K + conductances has been also demonstrated in rod bipolar cells isolated from the mouse retina (Bigiani et al., 2004) . In the same experimental model, sst 2 inhibits the K + -induced increase of [Ca 2+ ] i both in the cell body and in the axonal terminals (Casini et al., 2005) . Similarly, in the axonal terminals of rod bipolar cells isolated from the rat retina, SRIF strongly inhibits a K + -induced increase of [Ca 2+ ] i via L-type Ca 2+ channels (Johnson et al., 2001 ). This effect of SRIF is likely to be mediated by sst 2 receptors.
Functional role
The first observations of SRIF effects on mammalian retinal physiology reported an influence of the peptide on the amplitude of the ERG b-wave in the rabbit retina in vivo (Cunningham and Neal, 1983) , while some years later Zalutsky and Miller (1990) , working with rabbit eyecup preparations, found that application of low concentrations of SRIF affects the amplitude of the a-, b-and c-waves.
In their seminal work, Zalutsky and Miller also investigated the effects of SRIF application on the activity of different retinal cell types, demonstrating that SRIF actions are characterised by slow onset and long latency and providing the first account of the complexity of SRIF functional actions in the retina. Briefly, SRIF was observed to directly affect bipolar, amacrine and ganglion cells and to influence the horizontal cell network. In particular, all ganglion cell types are excited by SRIF, which also affects the centre-surround balance of their receptive fields.
The localisation of some of the SRIF receptors at locations that are distant from the sites of SRIF release in the inner plexiform layer suggests that this peptide may act in a paracrine fashion. In particular, SRIF functions are likely to result from the actions exerted by SRIF onto other neurotransmitter systems in the retina, including the release of SRIF itself. These effects are consistent with the documented SRIF control of K + /Ca 2+ conductances as well as the nitric oxide/cGMP pathway, which has been recently coupled to neurotransmission in the inner retina (Ding and Weinberg, 2007) . In addition, at the level of outer retina, SRIF coupling to Ca 2+ -dependent mechanisms provides important regulation of both rod and cone photoreceptor function, including transduction and synaptic transfer of light stimuli. In particular, in the outer segment, Ca 2+ controls photoreceptor light adaptation, while in the inner segment and synaptic terminal, Ca 2+ is involved in the regulation of cellular metabolism, glutamate release, cytoskeletal dynamics, gene expression and cell death (Krizaj and Copenhagen, 2002) .
Somatostatin control of its own release
SRIF may regulate its own release through sst 1 in different systems, including the retina . In particular, the observation that sst 1 is expressed by all SRIF-containing amacrine cells strongly suggests that sst 1 acts as an autoreceptor to limit SRIF release. Indeed, functional studies in rat retinal explants firmly established that sst 1 activation decreases SRIF release Mastrodimou and Thermos, 2004) . Additional, although indirect, evidence of the autoreceptor function of sst 1 derives from studies in sst 1 or sst 2 KO mouse retinas. As mentioned above, sst 1 KO retinas are characterised by increased levels of SRIF peptide, while sst 2 KO retinas display a significant decrease of retinal SRIF. These observations suggest that the amount of retinal SRIF is likely to depend on the expression levels of sst 1 (Casini et al., 2004) : in the absence of sst 1 (as in sst 1 KO retinas) inhibitory mechanisms limiting SRIF levels in the retina would be removed, while in the presence of sst 1 over-expression (as in sst 2 KO retinas) such mechanisms would be strengthened.
Somatostatin control of dopamine release
Based on the expression of SRIF receptors by tyrosine hydroxylase-containing, dopaminergic amacrine cells, SRIF control of dopamine release has been postulated in mouse, rat and rabbit retinas, although there are differences in the individual SRIF receptors that may mediate this control. The direct demonstration of an influence of SRIF on retinal dopamine release has been recently provided by Thermos and colleagues (Kouvidi et al., 2006) , who showed that activation of either sst 1 or sst 2 causes an increase of dopamine release in rat retinal explants, while activation of sst 3 has no effect. Since retinal levels of dopamine are known to be positively correlated with light intensity (Boelen et al., 1998; Djamgoz and Wagner, 1992) , this SRIF control of dopamine release is likely to have importance for the regulation of light adaptation.
Somatostatin control of glutamate release
Glutamate is the major excitatory neurotransmitter in the mammalian retina, and it is implicated in the neurotransmission along the vertical visual pathway from photoreceptors to bipolar cells to ganglion cells. A common trait of the somatostatinergic system among different mammalian retinas is the expression of sst 2A in rod bipolar cells, which represent a major source of glutamate in the retina. This observation indicates that an important, conserved functional role of SRIF in the retina is the regulation of glutamate release through an action at sst 2 . Consistently, sst 2 activation has been shown to inhibit K + -induced glutamate release in mouse retinal explants (Dal Monte et al., 2003a) .
In addition, the SRIF-induced inhibition of glutamate release is significantly stronger when sst 2 is over-expressed, as in sst 1 KO retinas (Bigiani et al., 2004) . A further indication that SRIF may limit glutamate release acting at sst 2 comes from recent studies where glutamate release was induced by ischemic treatment in a mouse retina preparation in vitro: in these conditions, glutamate release was significantly reduced in sst 1 KO retinas in comparison to WT retinas .
Together, these data concur to the notion that the SRIF system in the retina is an important regulator of the concentration of released glutamate in the extracellular space. This function is likely to represent an important contribution to the regulation of the glutamatergic transmission along the vertical retinal visual pathway. In addition, by limiting the amount of glutamate available to glutamate receptors, SRIF may also exert an important neuroprotective function against glutamate neurotoxicity that characterises many retinal diseases (see point 3).
Somatostatin effects on other neurotransmitters
The localisation of SRIF receptors to different types of amacrine cells in the inner nuclear layer, including glycine containing amacrine cells (Cristiani et al., 2002) , some cells likely belonging to subpopulations of GABAergic amacrine cells (Ke and Zhong, 2007; Cristiani et al., 2002) , or to horizontal cells, which are considered to be GABAergic (Vardi and Sterling, 1994) , suggests that SRIF may participate to the regulation of the retinal levels of these important inhibitory transmitters. Although functional evidence for a SRIF control of glycine release is lacking, SRIF has been suggested to enhance GABAergic transmission through phosphorylation of GABA A receptors in amacrine cells of the rat retina (Feigenspan and Bormann, 1994) . This possibility is intriguing in view of the fine control that GABAergic amacrine cells exert on transmitter release from rod bipolar cell terminals through GABA C receptors (Vaquero and de la Villa, 1999) . If these GABAergic amacrine cells respond to a regulation by SRIF, this peptide would be able to control glutamate release by the rod bipolar cells through two distinct mechanisms: a direct action onto the sst 2A expressing rod bipolar cells, and an indirect action by regulating GABA release from amacrine cells.
The fact that sst 5 may be expressed by cholinergic amacrine and displaced amacrine cells (Ke and Zhong, 2007) , suggests that SRIF may be involved in the control of acetylcholine release. However, earlier investigations showed that SRIF does not change the level of light-evoked release of acetylcholine from rabbit retina (Cunningham and Neal, 1983) .
The somatostatinergic system in retinal diseases
The wide anatomical distribution and multiple actions of SRIF and its receptors have stimulated intense clinical studies, and the SRIF system is currently a therapeutic target for different pathological conditions Panteris and Karamanolis, 2005; . SRIF analogues are either peptidic or non-peptidic compounds that equally bind to the majority of SRIF receptors (Armani et al., 2007; Ludvigsen et al., 2007; Nolan et al., 2007; Zatelli et al., 2007; Batista et al., 2006; Cervia et al., 2005a; van der Hoek et al., 2005; van der Hoek et al., 2004; Lewis et al., 2003; Reubi et al., 2002) , or are selective for a specific SRIF receptor subtype or class (Cervia et al., 2005b; Olias et al., 2004; Weckbecker et al., 2003) . In addition, the emergence of novel multispecific SRIF analogues (compounds targeting different cellular receptors) and conjugates (synthesised by chemically linking SRIF analogues with other agents) with improved receptor specificity may produce a new generation of potential drugs (Dasgupta, 2004) . On the basis of laboratory findings, the possible clinical use of SRIF analogues in ophthalmology has been suggested (Casini et al., 2005; Missotten et al., 2005) . However, difficulties with the route of administration, dosage, and adverse effects may compromise the translation to the clinics.
Retinal ischemia
Ischemia deprives a tissue of three requirements: oxygen, metabolic substrates, and removal of waste products. The loss of these requirements will initially lower homeostatic responses and with time will induce injury to the tissue due to cell loss by apoptosis (Osborne et al., 2004) . Ischemia can be considered as a sort of final common pathway in retinal diseases. It is a primary cause of neuronal death and is a common cause of visual impairment and blindness. To contrast this pathological state, specific pharmacological strategies need to be developed aimed at the many putative cascades generated during ischemia (Osborne et al., 2004) . Among pharmacological targets, the SRIF system is a candidate that is being subjected to intensive investigation. Indeed, there is evidence that retinal SRIF may act as a neuroprotective agent in ischemic retinas (Casini et al., 2005) . In particular, in guinea pig retinas, octreotide (a long-lasting sst 2 preferred agonist)
protects against ischemia-reperfusion injury (Celiker and Ilhan, 2002) and sst 2 agonists attenuate cell death in rat retinal explants subjected to chemical ischemia (Mastrodimou et al., 2005) .
Recently, an altered expression of SRIF receptors has been shown to modulate retinal responses to cell damage in an in vitro model of the ischemic mouse retina . In particular, sst 1 KO retinas, where sst 2 are over-expressed and over-functional, display a marked reduction of cell death with respect to WT or sst 2 KO retinas. In addition, the expression of protease caspase-3 mRNA, a marker of apoptotic cell death, is also reduced in sst 1 KO as compared to WT retinas.
Taken together, these observations demonstrate that an increased presence/activation of functional sst 2 protects against retinal ischemia.
Immunohistochemical analyses have identified some of the retinal cell populations that are protected by sst 2 activation. In particular, in explants of the rat retina subjected in vitro to chemical ischemia, sst 2 agonists prevent, at least in part, the loss of several retinal cell populations, including choline acetyltransferase-, tyrosine hydroxylase-, nitric oxide synthase-positive amacrine cells as well as the rod bipolar cells (Mastrodimou et al., 2005) . On the other hand, other studies in a model of in vitro ischemia of the mouse retina have recently demonstrated that the extent of sst 2 -mediated protection may vary among different retinal cell populations , suggesting a high level of complexity within the neuroprotective mechanisms of sst 2 . For instance, it is interesting to note that the population of rod bipolar cells, which express sst 2 at high levels, is severely affected by ischemia, but it is significantly spared in the presence of sst 2 overexpression, as in sst 1 KO retinas, while it is more heavily damaged in the absence of sst 2 , as in sst 2 KO retinas (Fig. 3) .
It is generally accepted that an important component of ischemic retinal injury involves neuronal
depolarisation and increased glutamatergic stimulation. Other factors may also play a part in neuronal susceptibility during ischemia and they include the ability to modulate Ca 2+ homeostasis, extracellular pH and the cells' ability to quench free radicals (Osborne et al., 2004) . Regarding the mechanism of action underlying SRIF neuroprotective effects in mouse ischemic retinas, sst 2 may act through the involvement of presinaptically sst 2 -mediated modulation of K + and Ca 2+ conductances leading to cell hyperpolarisation, [Ca 2+ ] i decrease and reduction of glutamate release (see paragraph 2.4.3.). sst 2 may also regulate, postsinaptically, NMDA receptor activation by glutamate as well as K + and Ca 2+ voltage-dependent channels. Neuroprotective effects of SRIF on NMDA-induced neuronal death have been previously shown in rats (Forloni et al., 1997) . In addition, in an in vitro model of chemical ischemia of the mouse retina, it has been recently demonstrated that not only retinal glutamate release increases under ischemic conditions (consistent with a role of glutamate excitotoxicity in ischemia-induced neuronal death), but also that this increase is significantly reduced in sst 1 KO retinas, indicating that the protection provided by increased presence of functional sst 2 is likely to be mediated by sst 2 modulation of glutamate release . Other mechanisms may also participate in the protective role of SRIF against retinal ischemia, such as an sst 2 -mediated regulation of nitric oxide, an important mediator in the pathogenesis of retinal ischemic damage (Osborne et al., 2004) . However, in guinea pig retinas, SRIF analogues do not seem to influence nitric oxide activity, which is decreased as a consequence of retinal ischemia-reperfusion (Celiker and Ilhan, 2002) .
Diabetic retinopathy
The concept that ischemia is the driving force for new vessel formation in the retina can be traced back over 50 years (Osborne et al., 2004) . Indeed, retinal ischemia is commonly caused by vascular closure with liberation of vasoproliferative factors, which in turn produces neovascularisation.
Ocular neovascularisation and the associated hemorrhages and fibrovascular proliferations are the underlying threats to vision in diverse conditions such as diabetic retinopathy, a leading cause of visual loss in industrialised countries. Laser photocoagulation remains the only procedure recommended for severe nonproliferative or proliferative retinopathy (Porta and Allione, 2004) , but this is an invasive procedure and provides only temporary protection (Croxen et al., 2004) . Less destructive approaches are desirable, and the use of SRIF analogues is currently tested in clinical trials with some success (Boehm, 2007; Palii et al., 2007; Croxen et al., 2004; Sjolie and Moller, 2004) .
SRIF levels in the vitreous of patients with diabetic retinopathy are significantly lower than those in nondiabetic control subjects (Hernandez et al., 2005; Simo et al., 2002) . This observation suggests that the intravitreous deficit of SRIF may contribute to the process of retinal neovascularisation typical of proliferative retinopathy and supports the concept that adequate levels of SRIF are needed for the maintenance of retinal homeostasis. Furthermore, there is a general agreement that SRIF may contrast neovascularisation associated with diabetic retinopathy, although the mechanism of action remains to be elucidated (Boehm, 2007; Casini et al., 2005) . Angiogenesis is a complex process, but it may be regarded as the result of changes in the equilibrium between anti-and proangiogenic factors. For instance, the insulin-like growth factor-1 (IGF-1), stimulated by growth hormone, increases in the vitreous of diabetic retinopathy patients (Simo et al., 2002) , and it is a major pro-angiogenic factor (DeBosch et al., 2001) . SRIF analogues are powerful inhibitors of growth hormone release and, therefore, decrease the blood IGF-1 concentration. Thus, SRIF may exert its antiangiogenic effects on the retina through antagonism of the growth hormone axis (Boehm, 2007; Wilkinson-Berka et al., 2006; Garcia de la Torre et al., 2002) . On the other hand, SRIF may inhibit retinal angiogenesis through autocrine and paracrine effects, perhaps directly on retinal cells or on retinal blood vessels (Boehm, 2007; Baldysiak-Figiel et al., 2004; Dasgupta, 2004; Garcia de la Torre et al., 2002; Higgins et al., 2002) . These effects are likely to include regulation of the levels of angiogenesis-associated factors that are expressed in the retina, such as IGF-1/IGF-1 receptors and vascular endothelial growth factor (VEGF)/VEGF receptors. In particular, IGF-1 not only is in the blood depending on the levels of circulating growth hormone (see above), but it and its receptors are also expressed throughout the retina in vascular, neuronal and glial cells, and they are altered by hyperglycaemia and hypoxia (Wilkinson-Berka et al., 2006) .
For instance, the levels of IGF-1 receptor mRNA are increased in the retinas of mouse models of both diabetic retinopathy (Kuang et al., 2003) and hypoxia-induced proliferative retinopathy (Dal Monte et al., 2007) , although conflicting results have been reported in rat retinas (Leske et al., 2006; Leske et al., 2004; Averbukh et al., 1998) . Regarding the VEGF system, diabetic retinopathy and hypoxia/acidosis-induced proliferative retinopathy have been shown to cause overexpression of retinal levels of VEGF and its receptors, thus increasing microvascular permeability and angiogenesis (Dal Monte et al., 2007; Leske et al., 2004; Werdich et al., 2004; Witmer et al., 2003; McLeod et al., 2002; Witmer et al., 2002; Ellis et al., 2000; Gilbert et al., 1998) . In a recent analysis of hypoxia-induced neoangiogenic retinas of sst 1 /sst 2 KO mice, we have demonstrated that lack of sst 2 , as in sst 2 KO retinas, is associated with significantly higher levels of neovascularisation.
Moreover, enhanced SRIF function at sst 2 , as in sst 1 KO retinas, limits the hypoxia-induced increase of the pro-angiogenic VEGF, whereas sst 2 loss upregulates this increase (Fig. 4) . In addition, the expression of the angiopoietin-1/2 and their receptors, which have different roles in the angiogenetic process, is dysregulated in the absence of sst 2 . (Dal Monte et al., 2007) . These observations provide evidence that sst 2 may be beneficial in limiting hypoxia-induced neovascularisation in the retina (Dal Monte et al., 2007; Kociok et al., 2006; Takagi et al., 2003) .
Another mechanism which may underlie anti-angiogenic effects of SRIF includes the involvement of the protein kinase CK2 (formerly casein kinase 2), an ubiquitous serine/threonine protein kinase that is involved in a wide variety of biological processes, including retinal angiogenesis and pathogenesis of diabetic and other proliferative retinal microangiopathies (Ljubimov et al., 2004) .
Indeed, a cross-talk between sst 2 and the CK2 pathway has been suggested on the basis that octreotide, combined with CK2 inhibitors, blocks retinal neovascularisation in a mouse model of oxygen-induced retinopathy more efficiently than either compound alone (Kramerov et al., 2006) .
Conclusion
Although far from being fully elucidated, SRIF modulation of ionic conductances, intracellular effectors and transmitter release in the retina may account for the observed effects of SRIF on retinal visual processing. In addition, SRIF may act as a positive factor in the retina by regulating retinal homeostasis and protecting neurons against damage. In this respect, SRIF analogues seem to 
